Physician profile
Richard Dalaba
NPI 1770745200
$26,171.04
in general payments reported to CMS, 2019-2025
10 companies · $927 in 2025
The $927 reported for 2025 was more than what 89% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $5,639 · 2023: $4,255 · 2024: $4,689 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,199 · Food and Beverage: $1,850 · Travel and Lodging: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,199.12 |
| Food and Beverage | $1,850.16 |
| Travel and Lodging | $1,821.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $14,047.39 | 2021-2024 | Stratafix, Dermabond, Pds |
| Ethicon US, LLC | $6,816.67 | 2021-2025 | Stratafix, Dermabond, Pds |
| Zimmer Biomet Holdings, INC. | $1,577.48 | 2021-2025 | Avenir, Z1 Hip System, Rosa |
| Depuy Synthes Products, INC. | $1,386.57 | 2021 | |
| Depuy Synthes Sales INC. | $1,162.61 | 2021-2025 | Attune, Velys, Actis |
| Ethicon INC. | $378.16 | 2021 | |
| Stryker Corporation | $377.92 | 2021-2023 | Mako |
| Smith+Nephew, INC. | $222.34 | 2021-2024 | Journey II |
| Convatec INC. | $118.86 | 2024 | |
| Sanara Medtech INC. | $83.04 | 2025 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Dalaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.